Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers
Status:
Withdrawn
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Discomfort with contact lens wear is the biggest reason why people stop wearing contact
lenses. The investigators believe that inflammation is one of the causes of discomfort, and
by blocking the inflammation using lifitegrast, the investigators may be able to relieve some
of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will
receive lifitegrast to use over a period of approximately 3 months.